Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Total Current Assets
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Total Current Assets Peer Comparison
600436
600276
000538
Competitive Total Current Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Total Current Assets
¥7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Assets
¥28.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Assets
¥15.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
21%
|
CAGR 10-Years
20%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Assets
¥31.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Assets
¥36.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Assets
¥775.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Total Current Assets?
Total Current Assets
7.3B
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Total Current Assets amounts to 7.3B CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
19%
Over the last year, the Total Current Assets growth was -19%. The average annual Total Current Assets growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been -2% over the past three years , 19% over the past five years .
You don't have any saved screeners yet
